Trial Profile
A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Infliximab
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms PURSUIT 2
- Sponsors Janssen Research & Development
- 12 Sep 2023 Planned End Date changed from 18 Apr 2031 to 31 Aug 2027.
- 15 Aug 2023 Planned End Date changed from 29 Jul 2025 to 18 Apr 2031.
- 28 Feb 2023 Planned primary completion date changed from 22 Dec 2022 to 20 Jun 2024.